Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
Thursday, the FDA approved Emergent BioSolutions Inc.'s EBS supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, L
Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine
07:15am, Friday, 30'th Aug 2024
The FDA approves the company's smallpox vaccine for Mpox.
US FDA approves use of Emergent's smallpox vaccine for people at high risk of mpox
07:21pm, Thursday, 29'th Aug 2024
Emergent BioSolutions on Thursday said the U.S. Food and Drug Administration (FDA) had approved expanded use of its ACAM2000 smallpox vaccine to include people at high risk for mpox infection.
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
11:30am, Tuesday, 20'th Aug 2024
GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliat
Emergent to donate 50,000 vaccine doses to address mpox outbreak in Africa
05:30pm, Monday, 19'th Aug 2024
Emergent BioSolutions said on Monday it would donate 50,000 doses of its vaccine, ACAM2000, to the Democratic Republic of the Congo and other impacted countries of Burundi, Kenya, Rwanda and Uganda to
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
05:10pm, Monday, 19'th Aug 2024
GAITHERSBURG, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it is proactively working with the World Health Organization (WHO) and the U.S. government to par
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
12:11pm, Monday, 19'th Aug 2024
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
09:00am, Sunday, 18'th Aug 2024
Emergent BioSolutions is a key player in public health. Its flagship product, NARCAN, is central to combating the opioid crisis. EBS stock rally is likely driven by its smallpox vaccine, ACAM2000, whi
Why Emergent BioSolutions Stock Is Skyrocketing Today
12:51pm, Friday, 16'th Aug 2024
The European Centre for Disease Prevention and Control raised its risk level for mpox on Friday. The World Health Organization declared a global public health emergency on Wednesday.
Health stocks jump as WHO declares mpox global health emergency
11:26am, Thursday, 15'th Aug 2024
Shares of Danish vaccine maker Bavarian Nordic jumped as much as 17% Thursday amid a wider rally for associated healthcare stocks. It comes after the World Health Organization declared an escalating m
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
11:47am, Wednesday, 07'th Aug 2024
On Tuesday, Emergent BioSolutions Inc. EBS reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million.
Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript
10:48pm, Tuesday, 06'th Aug 2024
Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
05:01pm, Tuesday, 06'th Aug 2024
GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2024.
Philadelphia, PA, July 31, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of RSDL® (Reactive Skin Decontamination Lotion) ki
